This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Discovery Labs Receives New US Patent For Pulmonary Surfactant Formulations

WARRINGTON, Pa., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced it has received a patent issued by the United States Patent and Trademark Office (USPTO) entitled "Pulmonary Surfactant Formulations." The claims of the patent (U.S. Patent Number 8,337,815) provide coverage for synthetic pulmonary surfactant compositions comprising a combination of a proprietary synthetic peptide and various lipids. The patent term expires in December 2028.

"The Company's strategy is to seek broad patent protection in the field of synthetic surfactants," said John G. Cooper, President and Chief Executive Officer at Discovery Labs. "This patent, together with our existing KL4 formulation patents covering SURFAXIN ® and combinations of pulmonary surfactant with protease inhibitors, as well as our patents covering methods of use and manufacture, provides a strong foundation for our continued leadership in the development of synthetic surfactants."

This patent provides exclusivity for new formulations of KL4 surfactant and is separate and distinct from the patent portfolios covering SURFAXIN, the Company's lead KL4 surfactant product, and AEROSURF ®, the Company's lead KL4 surfactant development program.

Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to advance a new standard in respiratory critical care. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized, and aerosolized dosage forms. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.

Discovery Labs' strategy is initially focused on the development of its technologies to improve the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, to significantly expand the current worldwide RDS market.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,643.78 +171.41 1.04%
S&P 500 1,975.63 +24.27 1.24%
NASDAQ 4,755.4510 +47.6760 1.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs